IN THE PRESS
STAT
Early Price Setting, Other Market Access Planning is Key for Early-Stage Drug, Device Companies
Back Bay Life Science Advisors
STAT
Microbiome Drug Development: A Rapidly Evolving Field
Back Bay Life Science Advisors
FIERCE CEO
Back Bay Life Science Advisors CEO Jonathan Gertler Helps Healthcare Companies Grow
Back Bay Life Science Advisors
LIFE SCIENCE LEADER
The Dynamics And Value Of Cross-Border Biotech
Jonathan P. Gertler, MD
WALL STREET JOURNAL VENTURE CAPITAL
Biotech Boosts Hopes for Long-Suffering IPO Market
Back Bay Life Science Advisors
WALL STREET JOURNAL VENTURE CAPITAL
Rise of ‘Earnouts’ Muddies M&A Waters | Founders, VCs Fear of More Disputes over Milestone Payments
Back Bay Life Science Advisors
WALL STREET JOURNAL VENTURE CAPITAL
Health-Care Returns Outpace Tech as Advances Reshape Industry
Back Bay Life Science Advisors
WALL STREET JOURNAL VENTURE CAPITAL
Health-Care VCs Emerge from Tech Investors’ Shadow
Back Bay Life Science Advisors